Literature DB >> 33174480

Dynamic analysis of m6A methylation spectroscopy during progression and reversal of hepatic fibrosis.

Zhongqi Cui1, Nan Huang1, Li Liu2, Xue Li1, Guohui Li3, Yan Chen1, Qi Wu1, Jie Zhang1, Shuping Long1, Minyi Wang1, Fenyong Sun1, Yi Shi2, Qiuhui Pan4.   

Abstract

Aim: To dynamically analyze the differential m6A methylation during the progression and reversal of hepatic fibrosis. Materials & methods: We induced hepatic fibrosis in C57/BL6 mice by intraperitoneal injection of CCl4. The reversal model of hepatic fibrosis was established by stopping drug after continuous injection of CCl4. Dynamic m6A methylation was evaluated using MeRIP-Seq in the progression and reversal of hepatic fibrosis at different stages. Result: During the hepatic fibrosis, differential m6A methylation was mainly enriched in processes associated with oxidative stress and cytochrome metabolism, while differential m6A methylation was mainly enriched in processes associated with immune response and apoptosis in the hepatic fibrosis reversal.
Conclusion: m6A methylation plays an important role in the progression and reversal of hepatic fibrosis.

Entities:  

Keywords:  N6-methyladenosine; differentially methylated genes; hepatic fibrosis progression; hepatic fibrosis reversal

Year:  2020        PMID: 33174480     DOI: 10.2217/epi-2019-0365

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  2 in total

1.  The m6A reader YTHDF3-mediated PRDX3 translation alleviates liver fibrosis.

Authors:  Ruimin Sun; Xinyao Tian; Yang Li; Yan Zhao; Zhecheng Wang; Yan Hu; Lijun Zhang; Yue Wang; Dongyan Gao; Shusen Zheng; Jihong Yao
Journal:  Redox Biol       Date:  2022-06-24       Impact factor: 10.787

2.  FTO promotes liver inflammation by suppressing m6A mRNA methylation of IL-17RA.

Authors:  Xiaojie Gan; Zhihui Dai; Chunmei Ge; Haozan Yin; Yuefan Wang; Jian Tan; Shuhan Sun; Weiping Zhou; Shengxian Yuan; Fu Yang
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.